CA1093071A - 5.alpha.-BICYCLOMYCIN DERIVATIVES - Google Patents

5.alpha.-BICYCLOMYCIN DERIVATIVES

Info

Publication number
CA1093071A
CA1093071A CA283,708A CA283708A CA1093071A CA 1093071 A CA1093071 A CA 1093071A CA 283708 A CA283708 A CA 283708A CA 1093071 A CA1093071 A CA 1093071A
Authority
CA
Canada
Prior art keywords
represents
lower
compound
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA283,708A
Other languages
French (fr)
Inventor
Beat Muller
Wilhelm Kump
Oskar Wacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to LU75516A priority Critical patent/LU75516A1/xx
Priority to LU75516 priority
Application filed by Ciba Geigy Investments Ltd filed Critical Ciba Geigy Investments Ltd
Application granted granted Critical
Publication of CA1093071A publication Critical patent/CA1093071A/en
Application status is Expired legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of products other than chlorine, adipic acid, caprolactam, or chlorodifluoromethane, e.g. bulk or fine chemicals or pharmaceuticals
    • Y02P20/55Synthetic design, e.g. reducing the use of auxiliary or protecting groups

Abstract

Case 4-10641/+
Canada Abstract of the Disclosure Bicyclomycin derivatives (i.e. compounds with the skeleton of the 5-methylene-2-oxa-7,9-diazabicyclo[4,2,2]decane) of the formula

Description

The present invention relates to bicyclic compounds with the basic skeleton of the 5-methylene-2-oxa-7,9-diazabicyclo[4, 4,2]clecane of the formula 5a 78N ~ 2 3 and in particular to derivatives of the bicyclomycin of the formula ~ - (CHSG~)n - X

NH lCO C~12 ~f 0/
I' a (I) CH3~ C - oRb 3CH2oRC

wherein each o~ Ra, Rb, Rc and Rd indi~idually represents a hydrogen atom or oxa-(low~r alkyl), oxa-(lower cycloalkyl), lower alkanoyl lower cycloalkoxycarbonyl or aroyl with no more than 7 carbon atoms, or any two of the symbols Ra, Rb and Rc together represent carbonyl, lower alkylidene or mono-cyclic lower cycloalkylidene, X represents carboxyl,

- 2 ~

- - - - - -~09;~071 cyano, car-bamoyl, carbazoyl, lower alkoxycarbonyl, phenyl-(lower alkoxy) carbonyl, lower alkanoyl or benzoyl, whereby phenylrin~s in the said radicals may be substituted by nitro, methoxy, lower alkyl and/or halogen, Y represents a hydrogen atom or has one of the meanings assigned to X, and n is O or 1, and of phar-maceutically acceptable salts of compounds which contain at least one carboxyl group, and also to a process for the manufacture of said compounds and to preparations which con-tain them and to the use thereof, as well as to therapeutic methods of combating infectious diseases which comprise the use of the said compounds and preparations.
In these compounds, the substituents at two carbon atoms forming a double bond can bein thecis- or trans-configuration, for example the symbol Y in relation to the cyclic portion of the molecule or the 6-hydroxyl group thereof. Unless otherwise specifically stated, eàch individual double bond can accordingly represent both a mixture of the two isomeric forms and an individual isomer.
For the sake of clarity, the nomenclature of the corsesponding compounds throughout the description and the Exam~les is derived fr~m bicyclomycin[systematic name:
6-hydroxy-5-methylene-1',2',3'-trihydroxy-2'-methylpropyl)-2-oxa-7,9-diazabicyclo[4,2,2]decane-8,10-dione] or from 5-norbicyclomycin [systematic name: 6-hydroxy-1-(9',2',3'-tri-~ ~ _ 3 _ ., ' :

hydroxy-2'-methylpropyl)-2-oxa-7,9-diazabicyclo[4,2,2]decane-8,10-dione] as basic substance; ~he carbon atom of the methylene group in the 5-position is designated 5a.
Oxa-(lower alkyl) or oxa-(lower cycloalkyl) are in par-ticular l-butoxyethyl or 2-tetrahydropyranyl.
Lower alkylidene formed by any two of the symbols Ra, Rb and Rc is in particular the isopropylidene radical which is bonded to the oxygen atoms in the 2',3'-position.
Unless stated to the contrary, the term "lower" used throughout this specification to qualify organic groups and radicals means that these contain not more than 7, preferably not more than 4, carbon atoms.
The phenyl-lower alkyl moiety in a phenyl-(lower alkoxy) carbonyl group is in particular a benzyl radical, which can carry in the phenyl moiety halogen atoms, such as chlorine, bromine, iodine and fluorine atoms, lower alkyl radicals, methoxy and nitro groups. Examples of particularly preferred lower alkoxy carbonyl groups are: methoxycarbonyl, ethoxy-carbonyl, propoxycarbonyl, butoxycarbonyl, tert-butoxycar-bonyl. Phenyl-(lower alkoxy)carbonyl is e.g. benzyloxycar-bonyl, ~-chlorobenzyloxycarbonyl, ~-nitrobenzyloxycarbonyl, ~-methoxybenzyloxycarbonyl, 2-phenylethoxycarbonyl, phenacyl-oxycarbonyl, ~-nitrophenacyloxycarbonyl and p-bromophenacyl-oxycarbonyl.
The carbamoyl and carbazoyl groups are preferably un-substituted.
~ - 4 -1~9307~

~ adicals in which a 6-membered aromatic ring (i.e. the benzene ring) is present are designated as aryl radicals.
A monovalent acyclic hydrocarbon radical is in particular a linear or branched lower alkyl radical. An acyclic ylidene radical is an analogous radical in which two free valencies originate from a single carbon atom and is in particular a lower alkylidene and lower alkenylidene radical.
Examples of lower alkyl radicals are methyl, ethyl.
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl, as well as n-pentyl, isopentyl, n-hexyl, isohexyl.
Examples of lower alkylidene radicals are methylene, iso-propylidene or isobutylidene.
A cycloalkylidene radical is a radical in which two free valencies originate from a single carbon atom.
Examples of cycloalkyl radicals are cyclopropyl, cyclo-butyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, and examples of cycloalkylidene radicals are cyclopentylidene or cyclohexylidene.
An aryl radical is in particular a phenyl radical.
Examples for aryl-lower alkoxycarbonyl groups are2-phenyl-2-propoxycarbonyl, 2-p-tolyl-2-propoxycarbonyl, l,l-diphenyl-ethoxycarbonyl or p,p'-dimethoxybenzhydryloxycarbonyl.
The c~mpounds of the formula I ca~l be in the form of salts, preferably of physiologically tolerable salts, if a free carboxyl group is pre~ent as substituent X and/or Y.
Such salts are in particular metal or ammonium salts, such as ~ - ~ - 5 -. .

.',. '' '' " ''`, ~, .
.

109307~

alkali metal and alkaline earth metal salts, for examplesodium, potassium, magnesium or calcium salts, and also ammonium salts with ammonia or suitable organic amines.
Suitable amines as salt-forming components are in particular acyclic, carbocyclic and carbocyclic-acyclic primary,secondary and, most preferably, tertiary mono-, di- or polyamines, and heterocyclic bases, such as lower alkylamines, for example triethylamine, hydroxy-lower alkylamines, for example 2-hydroxy-ethylamine, di-(2-hydroxyethyl)-amine or tri-(2-hydroxyethyl)-amine, basic aliphatic est~rs of carboxylic acids, for example 2-(diethylamino~-ethyl 4 aminobenzoate, lower alkylenamines, for example l-ethyl-piperidine, cycloalkylamines, for example dicyclohexylamine, or benzylamines, for example N,N'-dib`enzyl-ethylenediamine, and bases of the pyridine type, for example pyridine, collidine or quinoline. Preferred salt-forming components are those which result in physiologically tolerable salts.
The novel compounds of the present invention exhibit useful pharmacological, especially antibiotic, for example antibacterial, properties, and/or they can be used as inter-mediates for obtaining such compounds.
Particularly preferred compounds are those of the formula :1093071 O~ C - (CH=CH)n ~ ~
,~
2 (IA) ~2 H- C - OH

C~3- C - OH

wherein XA represents carboxyl, . cyano, carbamoyl, carbazoyl, lower alkoxycarbonyl, phenyl - (lower alkoxy)carbonyl, lower alkanoyl or benzoyl, ~ represe'nts hydrogen or has the meaning assi~ned to XA, RA represents lower alkanoyl or aroyl with no more than 7 carbon atoms, or hydrogen, and n is O or 1, where-by phenyl rings in said radicals may be substituted by nitro, methoxy, lower alkyl and/or halogen, and pharmaceutically acceptable salts of compounds which contain carboxyl groups.
Halogen can be bromine and iodine and, in particular, fluorine or chlorine.
As has already been mentioned above, the novel compounds, in particular those of the formula IA, are distinguished by their u8eful pharmac~logical properties, as for example results o~ in vitro tests demonstrate. Accordingly, they possess for example antibio~ic, in particular antibacterial, _ 7 _ ~ ,~

. .
,' ' ~ 9307~L

properties, in that they i~hibit the growth of microorganisms, such as Enterobacteriaceae (in concentra~ions of approx. 12.5 to approx. 100 mcg/ml) or Proteus sp. (in concentrations of approx. 25 to approx. lOOmcg/ml), in the agar dilution test.
Compared with bicyclomycin, the novel compounds have fur~her-more the advantage that they are also active against Proteus sp.
Among these compounds, particularly preferred compounds are those of the formula yB

~' ~H ~0 CH2 (IB) H- C- OH

Ca20RB

~herein RB r~presents lower alkanoyl, aroyl with no more than 7 carbon atoms or hydrogen, X~ represents cyano or a group of the formula -CI~O)Z, yB has one of the meanlngq ass1gned to xB or represents hydrogen, and Z represents hydroqen, hydroxyl, amino, hydrazino, phenyl, lower alkyl, lower alkoxy or phenyl-(lower alkoxy), and the phenyl rings of all these radicals can be substituted by nitro, methoxy, me~hyl, chlorine or .

11~93~

fluerine, and pharmaceutically useful salts of compounds in which z represents hydroxyl.
The most preferred compounds are those of the formula IB, whereinRB represents a hydrogen atom, XB represents the cyano, carboxyl or Cl-C4-lower alkoxycarbonyl group and yB represents hydrogen or has one of the preferred meanings of XB, and pharmacologically useful salts of the compounds which contain free carboxyl groups. Among these compounds, mention is to be made for example of bicyclomycin-5a-carboxylic acid and the nitrile and, in particular, the methyl and ethyl ester thereof, and also the sodium and potassium salt thereof.
The novel compounds can therefore be used for example in the form of antibiotic preparations for the treatment of infectious diseases, or as disinfectants or preservatives, or as additives to animal feeds. In atdition, they can be used as intermediates for obtaining such compounds with antibiotic action.
The compounds of the formula I are obtained by reacting a 5-norbicyclomycin-5-one compound of the formula II
oRd o /~ ' ~H ~0 C1~2 CO ~H CH
2 (II) H- C - ORa C~3- C - ORb ~ - g -~.. .

1093(~71 wherein R , R , R and Rd are as defined in formula (I), with a compound of the formula X - (CH--CH)n - I - W (III) wherein X, Y and n have the indicated meanings and W 63 represents a trisubstituted phosphonio group or a diesterified phosphono group together with a cation, and, if a compound of the formula I is required, wherein at least one of the symbols Ra-Rd represents hydrogen, subjecting to hydrolysis a resultant compound, in which the respective sym~ol represents a hydroxyl protective group as defined hereinabove, and/or, if a compound of the formula I is required, wherein at least Rc represents an acyl group as defined hereinabove, treating a resultant hydroxy compound with a corresp~nding acid or a reactive derivative thereof, and/or, if a compound is required in which X is carboxyllsetting ~ree, by hydrolysis or hydrogenolysis, the carboxyl group in a resultant compound in which X repre-sents an esterified carboxyl group, and/or, if required, con-verting a resultant compound with a carboxyl group lnto a pharmaceutically acceptable salt or a resultant salt into the : free acidic compound or into another pharmaceutically accept-able salt, and~or, if required, separating individual isomers from a resultant isomer mixture.

5~ - 10-.

Starting materials of the formula II can contain both free and protected hydroxyl groups. However, a special temporary protection of free hydroxyl groups during the reaction of the present invention is not necessary in every case.
Starting materials of the formula III with a reactive phosphorus-containing functional group are designated as Wittig reagents. The group X ~ in the starting material of the formula (III) is a phosphoniQ or phosphono group which is ordinarily used in Wittig condensation reactions, in particular a triarylphosphonio, for example a triphenylphos-phonio group, or tri-lower alkylphosphonio, for example tri-butylphosphonio group, or a phosphono group which is di-esterified by lower alkyl, for examFle ethyl, and the symbol W 63, if it represents the phosphono group, additionally comprises the cation of a strong base, in particular a suit~ble metal ion, such as an alkali metal ion, for example a lithium, sodium or potassium ion. The group W 63 is preferably on the one had a triphenylphosphonio and tributylphosphonio group, and on the other, a diethylphosphono group together with an alkali metal ion, or example a sodium ion.
In phosphonium compounds of the formula (III), which in the isomeric ylene ~orm are also designated as phosphorane compounds, the negative charge is neutralised bythepositively charged phosphonium group. In phosphono compounds of the ~L093~37~

formula (III), which in their isomeric form can also be designated as phosphonate compounds, the negative charge is neutralised by the cation of a strong base which, depending on the method of preparing the phosphono starting material, can be for example an alkali metal ion, for example a sodium, lithium or potassium ion. The phosphonate starting materials are therefore used as salts in the reaction.
The actual reactive form is illustrated by formula (III), in which the reagent acts on the ketone component of the formula ~II). The starting material employed is however normally characterised by the alternative equivalent formula X - (CH-CH)n - C = Wl (IIIa) wherein X, Y and n have the above ~eanings and Wl represents a trisubstituted radical, in particular a triaryl-, for example tripheny~phosphoranylidene, radical, or a tri-lower alkyl-, ~or example tri-n-butyl-phosph~ranylidene radical, or, if the starting material is a phosphono compound, by the formula X ~ (Ca~CH)n - I _ w2 (IIIb) wherein X, Y and n have the indicated meanings and W~
represents a phosphono group, in particular a dialkylphos-~.. ; , ~093071 phono, for example diethylphosphono, group. It will be under-stood however that a phosphono starting material of the form~lla (IIIb) is used in the form of a salt through being converted into the salt form illustrated by formula (III) suitable for the condensation by treatment with a suitable basic reagent, such as an inorganic base, for example an alkali metal carbonate, for example sodium or potassium carbonate, or an organic base, such as a tri-lower alkylamine, for example triethylamine, or a cyclic base of the amidine type, such as a corresponding diazabicycloalkene eompound, for example 1,5-diaza-bicyclo[5.4.0]undec-5-ene.
If the Wittig reagent of the formula III contains functional groups, such as carbonyl or carboxyl groups, it is -with few exceptions - advantageous if these groups arP in a protected form. Carbonyl groups are preferably protected by ketalisation or acetalisation, preferred alcohol com~onents being the lower alkanols and lower alkanediols referred to abo~e. The exception is a radical X wherein the carbonyl group is in the l-position, in which case the carbonyl graup preferably remains free. Normally. compounds o the formula (III) contain no free carboxyl groups, the sole exception being phosphono compounts of the formula (IIIb) wherein X or Y represents a free carboxyl group in the form of a metal salt, preferably al~ali metal salt, such as a lithium, sodium or potassium salt. If it is desired to obtain a final product of the formula (I). wherein X and/or Y represents a free ~ - 13 -1093{)7~L

carboxyl group, preferably a starting material of the formula (III) is used, wherein the carboxyl group forms an es~erified carboxyl group with a group zx which can readily be replaced by h~ydrogen, especially under mild conditions. Such a group is in particular an a-polybranched l~wer alkyl group, for example a tert-butyl group, a lower alkenyl group, in particular a 2-lower alkenyl group, for example an allyl group, or a 2-halogeno-lower alkyl group, for example a 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl group; a 2-lower alkylsulphonyl-lower alkyl group, for example a 2-methylsulphonylethyl group, or a l-phenyl-lower alkyl group which is unsubstituted or substituted by lower alkoxy (for example methoxy) or by nitro, such as a benzyl or diphenyl-methyl group which is unsubstituted or substituted as indicated, for example the benzyl, 4-methoxybenzyl, 4-nitrobenzyl, di-phe~ylmethyl or 4,4'-dimetho~y-diphenylmethyl groupi and also an organic silyl group, such as a tri-l~wer alkylsilyl, for example trimethylsilyl, group. These groups zx areparticularly suitable for being split off after the Wittig reaction. The splitting-off is performed in a mamler known per se and is accompanied by libera~ion of the carboxyl group.
The process of the pre~ent in~ention is carried out in a manner which is known per se, preferably in the presence of a suitable inert solvent, for example in an aliphatic, cyclo-aliphatic or aromatic hydrocarbon. for example hexane, cyclo-.~
~4 '5'.`X,~

~093'~)7~

hexane, benzene or toluene, a~halos~enated hydrocarbon, forexample methylene chloride, an ether, for example diethyl ether, a lower alkylene glycol di-lower alkyl ether, for example dimethoxyethane or diethylene glycol dimethyl ether, a cyclic ether, for example dioxane or tetrahydrofurane, a carboxamide, for example dimethyl forma~ide, a di-lower alkyl sulphoxide, for example dimethyl sulphoxide, or a lower alkanol, for example methanol, ethanol or tert-butanol, or in a mixture thereof, and, if necessary, in an inert gas atmos-phere, for example in an atmosphere of argon or nitrogen, and preferably in the absence of water. The reaction can take place at room temperature, but in most cases it is assisted advantageously by heating, for example in the temperature range between 30 and 120C, preferably between approx. 50 and approx. 100C.
Protected hydroxyl groups in the final products of the formula (I), ca~, if desired, be set free in a manner known per se individually or together. Accordingly,for example, hydroxyl groups which are protected as tetrahydropyranylether, such as those in the 1',3'- and/or 6-position, or as acetonide, such as those in the 2',3'-position, can be set free by conventional acid catalysed hydrolysis.
H~wever, in final products of the formula (I) which contain at least one hydroxyl group, for example in which at least one of the sym~ols Ra, Rb, Rc and Rd represen~s hydrogen, ~ - 15 -~;;~s ~ 09 3 0 7~

the hydroxyl group can be esterified by methods which are known per se, in particular by treatment with acids, such as carboxylic acids, or with reactive derivatives there~f, such as anhydrides, halides, for example chlorides, and ketenes.
A ketalised or acetalised oxo group present in a compound of the formula (I) can be converted in a manner which is known per se into the free oxo group, for example by conventional acid catalysed hydrolysis.
A free oxo group present in an final product of the formula I can be converted into a functionalised oxo group, for example into the corresponding oxime in a manner known per se by treatment with hydroxylamine or with an O-substituted, such as O-lower alkylated, hydroxylamine, or with an acid addition salt of these compounds. If such an oxo group is at a suitable distance from the free hydroxyl group in the 6-position, as is the case for example of a carbonyl group which is bonded to the 5a-carbon atom, then both groups can combine to form a cyclic hemiketal (cf. Example 16). A free oxo group can also be functionally modified in such a manner that it is reduced in a manner known per se to form a corresponding hydroxyl group. For this purpose, diborane or c~mplex metal hydrides, in particular baron hydrides, such as potassium or especially sodium borohydride, are used.
In a final product of the formula (I),wherein a carboxyl group together with a group zx which can be easily replaced ~ 16 -1093~71 by hydrogen forms an esterified carboxyl group, this latter can be converted into the free carboxyl group in a manner known per se, for example depending on the nature of the group zx Accordingly, a carboxyl group which is esterified by a suitable 2-halo-l~wer alkyl, arylcarbonylmethyl or 4-nitroben2yl group can be converted into the free carboxyl group by treatment with a reducing agent, such as a metal, for example zinc, or with a reducing metal salt, such as a chromium(II) salt, for example chromium(II) chloride, usually in the presance of a hydrogen donor which, together with the metal, is able to produce nascent hydrogen, such as of an acid, in particular acatic a~id, and also formic acid, or of an alcohol, preferably with the addition of water. Starting from a suitably esterified form, the carboxyl group can also be set free as follows:
a carboxyl group which is esterified by an arylcarbonylmethyl group: by treatment with a nucleophilic, preferably salt-forming reagent, such as sodium thiophenolate or sodium iodide, a carboxyl group which is esterified by 4-nitrobenzyl: by treatment with an alkali metal dithionite, for example sotium dithionite, a carboxyl group which is esterified by a 2-lower alkyl-sulphonyl-lower alkyl group: by treatment with a base, a carboxyl group which is esterified by a suitable arylmethyl lU93~7~

group: by irradiation with ultra~iolet light, for example at wavelengths under 290 m~ if the arylmethyl group represents a benzyl radical which can be substituted in the 3-, 4- and/or 5-position, for example by lower alkoxy and/or nitro groups, or with wavelengths above 290 m/u if for example the arylmethyl group represents a benzyl radical which is substituted in the 2-position by a nitro group, a carboxyl group which is esterified by a suitably substituted me~hyl radical, such as tert-butyl or diphenylmethyl: by treatment with a suitable acid agent, such as formic acid or trifluoroacetic acid, optionally with the addition of a nucleophilic compound, such as phenol or anisol, an esterified carboxyl group which can be split by hydrogenolysis, for example a benzyloxycarbonyl or 4-nitrobenzyloxycarbonyl group:
by hydrogeno~ysis, for example by treatment with hydrogen in the presence of a noble metal catalyst, for example apalladium catal~st.
In resultant final-products of the formula (I), free or functionally modified carboxyl groups can be con~erted into other functionally modified carboxyl groups in a manner which is known per se.

Accordingly, for example, it is possible to esterify a free carboxyl group. Esterification is effected for example by treating the free acid with a suitable diazo compound~ such as a diazo-Lower alkane, for e~ample diazomethane or diazo-~t~' ~

109307~

butan.e, or with a phenyldiazo-lower alkane, for example diphenyldiazomethane, if necessary in the presence of a Lewis acid, for example boron trifluoride. The esterification is also carried out by reaction with an alcohol in the presence of an esterifying agent, such as a carbodiimide, for example dicyclohexylcarbodiimide, or carbonyldiimidazole, as well as with a ~,N'-disubstituted 0- or S-substituted isourea or iso-thiourea in which the 0- or S-substituent is for example lower alkyl, in particular tert-butyl, phenyl-lower alkyl or cycloal~yl, and the N- and/or N'-substituents are for example lower alkyl, in particular isopropyl, cycloalkyl or phenyl radicals. Known and suitable estexification methods include for example the conversion of the free carboxyl group into a salt and the reaction of the salt with a reactive ester of an alcohol and a strong mineral acid or organic sulphonic acid, as well as the primary formation of the acid halidec~
for example chlorides (prepared for example by treatment with oxalyl chloride), of activated esters (formed for example with a M-hydroxysuccinimide) or of mixed anhydrides (obtained for exa.mple with lower alkyl esters of haloformic acid, such as ethyl chloroformate or isobutyl chloroformate, or with halo-acetic halides, such as trichloroacetyl chloride) and reaction ~l ~ . ., 3L~93~7~

of these reactive intermediates with alcohols, optionally in the presence of a base, such as pyridine.
These reactive intermediates can also advantageously be used as intermediate steps for the conversion of a free carboxyl group into a carbamoyl or carbazoyl group the nitrogen atoms of which can be substituted, for example in particular by lower alkyl radicals, in which case such a reactive com-pound is treated with ammonia or hydrazine hydrate, or with a N-substi~uted, in particular N-lower alkylated, derivative thereof, in a manner which is known per se. Carboxyl groups which are present in the fin~l products of the formula (I) can also be converted with the same nitrogen-containing reagents into the corresponding carbamoyl and carbaz,oyl groups.
Salts of compounds of the form~la I can be prepared in a manner kn~wn per ~e. Thus salts of compounds of the formula I
with a free carboxyl group can be formed for example by treatment with metal compounds, such as hydroxides, carbonates and hydrocarbonates of alkali metals or alkali metal salts of suitable carboxylic acids, for example with the sodium salt of a-ethylcaproic acid, or with ammonia or a suitable organic amine, preferably using stoichiometric amounts or only a small excess of ~he salt-forming agent.
Salts can be converted in the customary manner into the free compounds, metal and ammonium salts for example by treatment with suitable aoids.

~ . .~ .~

~V9307~

Resultant mixtures of stereoisomers can be separated into the individual isomers by methods which are known per se, for example by fractional crystallisation, adsorption chromato-graphy (column or thin-layer chromatography), or other appropriate methods of separa~ion.
The process also comprises those embodiments of the invention in which compounds obtained as intermediates are used as starting materials and the remaining process steps are carried out therewith or in which the process is interrupted at any stage, or in which starting materials can be used in the form of derivatives or formed during the reaction.
Preferably, the starting materials and reaction conditions are so chosen that the compounds referred to at the outset as being especially preferred are obtained.
The ~tarting materials of the formula II used in accordance with the invention can be obtained by the oxidative elimination of the methylene group, for example by ozonisation, of the bicyclomycin or of a derivative thereof with protected hydroxyl groups, as described in British Patent No. 1545021.

Compounds of the formula (IIIa) and (IIIb) are known or they can be obtained by methods which are known per se.
The pharmacologically useful compounds of the present invention can be used for example for obtaining pharmaceutical preparations which contain an effective amount of the active ~ s~ - 21 -t~t ~ ;~, ~09 3~ 7 ~

subst:ance together or in admixture with inorganic or organic solicl or liquid pharmaceutically useful carriers, which are suitable preferably for enteral, such as oral, or parenteral, administration.
Tablets or gelatin capsules are therefore used which contain the active substance together with diluents, for example lactose, dextrose, saccharose, mannitol, sorbitol, cellulose and/or glycin, and lubricants, for e~ample silica, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Tablets also contain binding agents, for example ~agnesium aluminium silicate, starches, such as maize, wheat, rice or arr~w root starch, gelatin, tragacanth, methyl cellulose, sodium carboxy-methyl cellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorption agents, colourants~ flavouring matters and sweeteners. Preferably the pharmacologically active compounds of the present invention are used in the form of preparations which can be administered by injection, or example, by intravenous injection, or of infusion solutions.
Such solutions are preferably isotonic aqueous solutions or suspensions which can be prepared before use, for example ~rom lyophilised preparations that contain the active sub-stance alone or together with a carrier, for example mannitol.

.

~Q9307~

The pharmaceutical preparations, can be sterilised and/or contain adjuvants, for example preservatives, stabilisers, wetting agents and/or emulsifiers, solubilisers, salts for regulating the osmotic ~ressure and/or buffers. The pharma-ceutical preparations which, if desired, can contain further pharmacologically useful substances, are manufactured in known manner, for example using conventional mixing, granulating, confectioning, dissolving or lyophilising methods, and they contain from about 0.1% to 100%, especially from about 1% to about 50%, and lyophilisates up to 100% of the active sub-stance. In particular, pharmaceutical preparations are pre-pared as dosage units.
The following non-limitative Examples will serve to illustrate the invention.
Preparation of the startin~ mate ials A) A fl~w of ozone-enriched oxygen is introduced at -70C
at a speed of approx. 20 litres/hr into a solution of 8 g of bicyclomycin monohydrate in 350 ml of methanol. After about 45 minutes, when a permanent blue colouration ensues, 2.2 ml of dimethyl sulphide are added and the reaction mixture i9 brough gradually to 0C. The crystallised protuct i9 collected with suction and the mother liquor is concentrated to about a third of its volume and allowed to stand in order to obtain the second crop of crystal~ o the same quality. The resultant 5-nor-bicyclomycin-5-one has a melting point of 160-162C, .~i ~, . .

~ 7 ~

which rises to 171-175C after crystallisation from ethyl acetat:e-methanol.
B) A solution of 11.5 g of bicyclomycin-6,1',3'-tri-tetrahy-dropyranyl ether in 200 ml of methanol is ozonised as described in A) and treated with dimethyl sulphide. After it has warmed to room temperature, the reaction mixture i5 concentrated and the residue dissolved in a very small amount of ether. The solution is added dropwise into petroleum ether and the white amorphous precipitate is collected with suction and dried in a high vacuum. The resultant 5-nor-bicyclomycin-5-one-6,1',3'-tri-tetrahydropyranyl ether melts unsharp between 65 to 75C.
C) 3 g of bicyclomycin-3'-benzoate in methanolic solution are ozonised under the conditions of A). The excess ozone is destroyed with dimethyl sulphide and the solution is concen-trated in a water ~et vacuum. The residue is precipitated ~rom methanol with ethyl acetate and yields amorphous 5-nor-bicyclomycin-5-one-3'-benzoate with a melting point of 125-130C.
D) A solution of 36 g of 5-norbicyclomycin-5-one in 600 ml of acetone and 1200 ml of dioxane is stirred with 360 ml of 2,2-dimethoxypropane (acetone dimethylketal) and 0.6 g of p-toluenesulphonic acid is added. The reaction mixture is stirred for 20 hours at room temperature, treated with 3.5 ml of triethylamine and concentra~ed in a water jet vacu~m. The `:~
~,..~;....; ., 109 3~7 1 residue is dissolved in ethyl acetate and precipitated by addition of ether, affording 5-norbicyclomycin-S-one-2',3'-acetonide with a melting point of 193-195C.
Exam~le 1 A mixture of 18.2 g of 5-nor-bicyclomycin-5-one in 60 ml of dioxane is treated with 20 g of methoxycarbonylmethylene-triphenylphosphorane and heated for 2 hours to 70C with stirring. The solvent is distilled off in a wat~r jet vacuum and the residue is chromatographed through 200 g of silica gel Elution with a 4:1 mixture (v/v) of chloroform/methanol yields a product which, after crystallisation from water, gives 5a-methoxycarbonylbicyclomycin with a melting point of 135-136C.
Example 2 Following the procedure of Example 1, a mixture of 1.82 g of 5-norbicyclomycin-5-one, 1.80 g of cyanomethylene-triphenyl-phosphorane and 60 ml of dioxane is stirred at 70C for 1 hour and worked up. On chromatography through 100 g of silica gel, elution with a 4:1 mixture (v/~) of chloroform/ma~hanol yields a crude product which is recrystallised from acetonitrile to gi~e Sa-cyanobidyclomycin with a melting point of 180C
(with tecomp.), Example 3 Following the procedure of Example 1, a mixture of 3.04 g of 5-norbicyclomycin-5-one, 3.48 g of ethoxycarbonylmethylene-triphenylphosphorane and 100 ml of dioxane is stirred for ~? - 25 _ 1093~71 2 % hours at 7~C and worked up. On chromatography through 180 g of silica gel, elution with a 4:1 mixture (v/v) of chloroform/methanol yields a crude product which is recrystal-lised from water to give 5a-ethoxycarbonylbicyclomycin with a melting point of 128~-130C.

ample 4 Following the procedure of Example 1, a mixture of 3.04 g of 5-norbicyclomycin-S-one, 4.55 g of 4-nitrobenzyloxycarbonyl-methylene-triphenylphosphorane and 100 ml of dioxane is stirred for 5 hours at 70C and worked up. On chromatography through 200 g of silica gel, elution with a 4:1 mixture (v/v) of chloroform/methanol yields a crude product which is crystallised from ethyl acetate to give 5a-(4-nitrobenzyloxy-carbonyl)-bicyclomycin with a melting point of 165-169C.

Exam~le 5 A mixture of 2.4 g of Sa (4-~itrobenzyloxycarbonyl)-bicyclo-mycin and 0.12 g of 10% palladium on charcoal in 100 ml of ethanol is hydrogenated at room temperature ant clightly raised (by a few mm/Hg) pressure for 24 hour~, in the coursq of which 473 ml of hydrogen is ta~en up. The catalyst is removed by filtration, the solution concentrated in a water jet vacuum and the resitue is chromatographed through 40 g of silica gel, Elution with a 4:1 mixture (v/v) of chloroform/
methanol yields 5a-carboxybicyclomycin in amorphous form.
~ 26 -, ~ ~ .7 . :. . .
: ' ' ' '. ' .' " ' , ' ~09;~071 Example 6A mixture of 6.5 g of 5-nor-bicyclomycin-5-one-6,1',3'-tri-tetrahydropyranyl ether and 4,06 g of ethoxycarbonylmethylene-triphenylphosphorane in 175 ml of benzene is stirred ~or 5 hours at 70C. The solution is concentra~ed and the residue is chromatographed through 200 g of silica gel, Elution with a 95:5 mixture (v/v) of chloroform/methanol yields crude 5a-ethoxycarbonylbicyclomycin-6,1',3'-tri-tetrahydropyranyl ether, This ether is dissolved in 50 ml of methanol and the solution is treated with 20 ml of 50% (v/v) aqueous acetic acid. The mixture is stirred for 15 hours at 50C and con-centrated in a water jet vacuum and the residue is chromato-graphed through 120 g of silica gel. Elution with a 4:1 mixture (v/v) mixture of chloroform/methanol yield~ a crude product which melts at 128-130C after recrystallisation from water and is identical with the 5a-etho~ycarbonylbicyclo-mycin of Eæample 3.

ample 7 A mixture of 2.4 g of 5-nor-bicyclomycin-5-one-3'-benzoate in 100 ml of dioxane is treated with 2.08 g of carbamoylmethylene-triphenylphosphorane and heated with stirring for 2 hours to 50C. ~he solvent is distilled off in a water jet vacuu~ and the residue is chromatographed through 200 g of silica gel.
Elution with a 4:1 mixture (~/v) of chloroform/methanol ,., ,~ ~, ~ .... i .
.

1 0~ ~0 7~

yields a product which is crystallised from methanol to give 5a-car~amoylbicyclomycin-3'-benzoate melting over 200C (with deco~p.).

Example 8 A mixture of 6.88 g of 5-nor-bicyclomycin-5-one-2',3'-acetonide in 150 ml of dioxane is treated with 9.6 g of carbamoylmethylene-triphenylphosphorane and stirred for 1 hour to 50C. The solvent is tistilled off in a water jet vacuum and the residue is chromatographed through 250 g of silica gel. Elution with a 4:1 mixture (v/v) of chloroform/
methanol yields a product which is crystallised from acetone to give 5a-carbamoylbicyclomycin-2',3'-acetonide melting over 185C (with decomp.).

Example 9 A mixture of 1.36 g of 5a-carbamoylbicyclomycin-2lr3l-acetonide in 100 ml of methanol and 1.72 ml of 2N sulphuric acid is stirred for 4 hours at room temperature, neutralised with solid barium hydroxide (octahydrate), freed from precipitated barium ~ulphate by filtration and concentrated in vacuo. The residue is washed with methanol, affording 5a-carbamoylbi-cyclomycin with a melting point of 204-207C.

~' '~ ..~ ~t 1093Q7~.

Example 10 Following the procedure described in Example 8, a mixture of 10.3 g of 5-~.or-bicyclomycin-5-one-2',3'-acetonide, 9.9 g of cyanomethylene-triphenylphosphorane and 300 ml of dioxane is stirred for 7 hours at 60C and worked up. On chromatography through 500 g of silica gel, elution with a 9:1 mixture (v/v) of chloroform/methanol yields a crude product which is recrystallised from ethyl acetate to give 5a-cyanobicyclo-mycin-2',3'-acetonide with a melting point o 194-195C
(with decomp.).

ample 11 Following the procedure described in Example 8, a mixture of

3.44 g of S-nor-bicyclomycin-2',3'-acetonide, 5.31 g of 4-nitrobenzyloxycarbonylmethylene-triphenylphosphorane and 10~ ml of dioxane is stirred for 7 hours at 70C and worked up. On chromatography through 300 g os silica gel, elution with a 4:1 mixture (v/v) of chloroform/methanol yields a crude product which is crystallised from ethyl acetate/ether to give Sa-(4-nitrobenzyloxycarbonyl)-bicyclomycin-2'.3'-acetonide with a melting point of 126-128C.

Example 12 A solution o~ 2.5 g of 5-nor-bicyclomycin-5-one in 30 ml of dioxane is treated at room temperature with 2.8 g of phen-acylidene-tributylphosphorane and 0.95 g of 97% potassium ~ - 29 -1~3V71 tert~butylate and stirred for 24 hours at room temperature, filtered, and concentrated under reduced pressure. The oily residue is chromatographed through 400 g of silica gel.
Elution with a 5:1 mixture (v/v) of chloroform/methanol and a 4:1 mixture (v/v) of ethyl acetate/me~hanol yields a product which is recrystallised from ethanol/pentane togive 5a-benzoyl-bicyclomycin with a melting point of 136-146C.

Exam~le 13 A mixture of 18.1 g of 5-norbicyclomycin-5-one in 400 ml of dioxane is treated with 22.1 g of acetonyl-tributylphosphonium chloride and 6.72 g potassium tert-butylate. The reaction mixture is then stirred for 6 hours at room temperature, filtered, and concentrated in a water jet vacuum. Initially, the residue is preliminarily purified through 600 g of silica gel with a 4:1 mixture (~/~) of ethyl acetate/ethanol and then chromatographed once more through 700 g of silica gel with 4:1 mixture (v/v) of chloroform/methanol, yielding a product which, after precipitation from methanolic solution with ethyl acetate, gives the amorphous 5a-acetylbicyclo-mycin with a melting point of 111-119C.
Repetition of the same procedure starting from an equivalent amount of S-nor~icyclomycin-5-one-2',3'-acetonide yields 5a-acetylbicyclomycin-2',3'-acetonide which, after precipitation from a solution in ethyl acetate with ether, melts at 193-195.

.~

~09~0~1 Example 14 A mixture of 3.8 g of Sa-acetylbicyclomycin, 1 g of 0-methyl-hydroxylamine hydrochloride, 100 ml of ethanol and 1.8 ml of pyridine is stirred for 2 ~ hours at 50C and concentrated in a water jet vacuum. The residue is chromatographed through 100 g of silica geli elution with a 4:1 mixture (v/v) of chloroform/methanol, yields a product which is recrystallised from et~yl acetate to yield 5a~ methoxyiminoethyl)-~icyclo-mycin with a melting point of 112-116C.

Example 15 A solution of 2.2 g of 5a-acetylbicyclomycin in 50 ml of methanol is treated at 0 to 5C with 0.240 g of sodium borohydride in 2 portions, stirred for 1 hour at 0 to 5C
and subsequently concentrated in a water jet vacuum. The resitue is chromatographed through 20 g of silica geli elution with a 2:1 mixture (v/v) of chloroform/methanol, yields a product which is recrystallised from methanol/ethyl acetate to yield 5a~ hydroxyethyl)-bicyclomycin (a mixture of both epimers at the newly formed hydroxyl group) with a melting point of 175-182C.
Repetition of this procedure starting from an equivalent amount of 5a-acetylbicyclomycin-2',3'-acetonide affords Sa-(l-hydroxyethyl)-bicyclomycin-2',3'-acetonide (a mixture of poth epimers at the newly formed hydroxyl group) with a melting point of 114-119C (amorphous).

.;, 10~307i ample 16A mixture of 1.3 g of 5a-acetylbicyclomycin, 0.247 g of sodium cyanoborohydride and 0.266 g of methylamine hydro-chloride in 50 ml of dioxane is stirred overnight at room temperature, concentrated and poured onto a column of 75 g of silica gel. Elution with a 2:1 mixture of chloroform/
methanol yields the amorphous inner hemiacetal of the starting compound of the formula 30 / \CH
~ .
NH ~o C~2 ~f ~H~2 1~ ~ C--0~
C~3- ~ - OH

which meltR at 123-130C a~ter precipitation with ethyl acetate from a methanolic solution.

ample 17 A total amount o~ 3.6 ml of benzoyl chloride is ~tded at 0C
to a solution of 7.5 g of Sa-methoxycarbonylbicyclomycin in 45 ml of pyridine and the reaction mixture is thereafter stirred for 6 hours at room temperature. Water is then added dropwise to the reaction mixture and the solution is concentrated under reduced pressure. The residueis partitioned , '. 1 ~ - 32 -109~071 between ethyl acetate and water, the organic phase is washed neutral with water, dried over magnesium sulphate and concentrated once more. The residue is chromatographed through a column of 500 g of silica geli elution with a 9:1 mixture (v/v) of chloroform/methanol, yields a product which is reprecipitated from ethyl acetate/pentane to give 5a-methoxy-carbonylbicyclomycin-3'-benzoate with a melting point o~ 125-133C.
5a-Methoxycarbonylbicyclomycin-1',3'-dibenzoate with a melting point of 132-144C is obtained as by-product from another fraction of the above described chromatography after reprecipitation from chloroform/pentane.
Example 18 A mixture of 1.9 ml of isobutyl chloroformate and 20 ml of tetrahydrofurane is added dropwise over the course of 30 minutes to a vigorously stirred solution of 1.9 g of 5a-methoxycarbonylbicyclomycin in 40 ml of pyridine with cooling to -15C. The mixture is then stirred for 1 hour at -10C, filtered to remove precipitated pyridine hydrochloride. and concentrated in a high vacuum. Chromatogxaphy of the residue through silica gel with a 19:1 mixture (v/v) of chloroform/
methanol yields two components: the more rapidly eluted 5a-methoxybicyclomycin-1',3'-0-dicarbonate and the more slowly eluted amorphous 3'-0-isobutyloxycarbonyl-Sa-methoxy-carbonylbicyclomycin; [a]D= + 34 +l (C=0.877; dimethylsulphox-ide).
~ : - 33 -~ .

109;~071 Example 19 A mixture of 2.5 ml of isopropyl chloroformate and 20 ml of tetrahydrofurane is added dropwise over the course of 20 minutes to a vigorously stirred solution of 2 g of 5a-methoxy-carbonylbicyclomycin in 30 ml of pyridine withcoolingto -15 c.
The mixture is then stirred for 1 hour at +10C, filtered to remove precipitated pyridine hydrochloride, and concentrated in a high vacuum. Chromatography of the residue through silica gel with a 19:1 mixture (v/v) of chloro~orm/methanol yields two components: the more rapidly eluted 5a-methoxycarbonyl-bicyclomycin-1',3'-0-dicarbonate and the more slowly eluted amorphous 3'-0-isopropoxycarbonyl-5a-methoxycarbonylbicyclo-mycin; [a]D ~ +56 + 1 (C-1.031; dimethyl sulphoxite).

am~le 20 A mixture of 3 ml of cyclohexyl chloroformate and 20 ml of tetrahydrofurane is added dropwise over thQ course of 20 minutes to a vigorously stirred solution of 2 g of 5a-methoxy-carbonylbicyclomycin in 20 ml of pyridine with cooling to -lS C.
The mixture is thereafter stirred for 1 hour at 0C, filtered to remove pre~ipitated pyridine hytrochloride, and concentrat-ed in a high vacuum. Chromatography of the residue through silica gel with a 19:1 mlxture (v/v) of chloroform/methanol ~'i lQ9~V71 yielcls 2 components: the more rapidly eluted 5a-methoxy-carbonylbicyclomycin-1',3'-0-dicarbonate and the more slowly eluted amorphous 3'-0-cyclohexyloxycarbonyl-5a-methoxycar-bonylbicyclomycin; [~D = +34 + (C = 1.033; dimethylsulphox-ide).

~' ~ Y

Claims (18)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for the manufacture of 2-oxa-7,9-diazabicyclo [4,2,2]decane compounds of the formula (I) wherein each of Ra, Rb, Rc and Rd individually represents a hydrogen atom or oxa-(lower alkyl), oxa-(lower cycloalkyl), lower alkanoyl lower cycloalkoxycarbonyl or aroyl with no more than 7 carbon atoms, or any two of the symbols Ra, Rb and Rc together represent carbonyl, lower alkylidene or mono-cyclic lower cycloalkylidene, X represents carboxyl, cyano, car-bamoyl, carbazoyl, lower alkoxycarbonyl, phenyl-(lower alkoxy) carbonyl, lower alkanoyl or benzoyl, whereby phenyl rings in the said radicals may be substituted by nitro, methoxy, lower alkyl and/or halogen, Y represents a hydrogen atom or has one of the meanings assigned to X, and n is 0 or 1, and of phar-maceutically acceptable salts of compounds which contain at least one carboxyl group, which process comprises reacting a 5-norbicyclomycin-5-one compound of the formula II

( II) wherein Ra, Rb, Rc and Rd are as defined in formula (I), with a compound of the formula.

(III) wherein X, Y and n are as defined in formula (I) and W+
represents a trisubstituted phosphonio group or a diesterified phosphono group together with a cation, and, if a compound of the formula I is required, wherein at least one of the symbols Ra-Rd represents hydrogen, subjecting to hydrolysis a resultant compound, in which the respective symbol represents a hydroxyl protective group as defined hereinabove, and/or, if a compound of the formula I is required, wherein at least Rc represents an acyl group as defined hereinabove, treating a resultant hydroxy compound with a corresponding acid or a reactive derivative thereof, and/or, if a compound is required in which X is carboxyl, setting free, by hydrolysis or hydrogenolysis, the carboxyl group in a resultant compound in which X repre-sents an esterified carboxyl group, and/or, if required, con-verting a resultant compound with a carboxyl group into a pharmaceutically acceptable salt or a resultant salt into the free acidic compound or into another pharmaceutically accept-able salt, and/or, if required, separating individual isomers from a resultant isomer mixture.
2. A process according to claim 1 wherein the reaction is carried out with a compound of the formula (IIIa) in which X, Y and n are as defined in claim 1 and W1 represents a triarylphosphoranylidene or tri-lower alkyl phosphoranylidene group.
3. A process according to claim 2 wherein the reaction is carried out with a compound of the formula (IIIa), in which w1 represents the triphenylphosphoranylidene or tributyl-phosphoranylidene group.
4. A process according to claim 1 wherein the reaction is carried out with a compound of the formula (IIIb) in which X, Y and n are as defined in claim 1 and W2 represents a dialkylphosphono group, said compound being in the form of a salt with a basic reagent.
5. A process according to claim 4 wherein the reaction is carried out with a compound of the formula (IIIb), in which W2 represents a diethylphosphono group, and the basic reagent is an alkali metal carbonate.
6. A process according to claim 1 wherein a resultant com-pound in which X represents p-nitrobenzyloxycarbonyl is con-verted by catalytic hydrogenation to a corresponding compound in which X represents carboxyl.
7. A process according to any one of claims 1, 2 and 4, wherein starting materials are selected such as to manufacture a compound of the formula I wherein Rb and Rc together represent an isopropylidene group and the other symbols have the meaning given in claim 1.
8. A process according to claim 1, wherein starting mate-rials are selected such as to manufacture a compound of the formula (IA) wherein Xa represents carboxyl, cyano, carbamoyl, carbazoyl, lower alkoxycarbonyl, phenyl-(lower alkoxy)carbonyl, lower alkanoyl or benzoyl, YA represents hydrogen or has the meaning assigned to XA, RA represents lower alkanoyl or aroyl with no more than 7 carbon atoms, or hydrogen, and n is 0 or 1, whereby phenyl rings in said radicals may be substituted by nitro, methoxy, lower alkyl and/or halogen, and pharmaceu-tically acceptable salts of compounds which contain carboxyl groups.
9. A process according to either of claims 2 and 4, wherein starting materials are selected such as to manufacture a compound of the formula (IA) indicated in claim 8 wherein XA
and Y are as defined in claim 8, n is 0, and RA represents lower alkanoyl or benzoyl or hydrogen, and the phenyl ring of said radical can be substituted by nitro, methoxy, methyl and/or halogen.
10. A process according to claim 1, wherein starting mate-rials are selected such as to manufacture a compound of the formula (IB) wherein RB represents lower alkanoyl, aroyl with no more than 7 carbon atoms or hydrogen, XB represents cyano or a group of the formula -C(=O)Z, YB has one of the meanings assigned to XB or represents hydrogen, and Z represents hydrogen, hydroxyl, amino, hydrazino, phenyl, lower alkyl, lower alkoxy or phenyl-(lower alkoxy), and the phenyl rings of all these radicals can be substituted by nitro, methoxy, methyl, chlorine or fluorine, and pharmaceutically useful salts of compounds in which Z represents hydroxyl.
11. A process according to either of claims 2 and 4, wherein starting materials are selected such as to manufacture a compound of the formula (IB) indicated in claim 10 wherein RB represents a hydrogen atom, XB represents the cyano, car-boxyl or C1-C4-lower alkoxycarbonyl group, and YB is hydrogen or has the same meaning as X , and pharmaceutically useful salts of compounds which contain free carboxyl groups.
12. A process according to any one of claims 1, 2 and 3, wherein starting materials are selected such as to manufacture a compound selected from a group consisting of bicyclomycin-5a-carboxylic acid and the nitrile and lower alkyl esters thereof.
13. A process according to any one of claims 4, 5 and 6, wherein starting materials are selected such as to manufacture a compound selected from a group consisting of bicyclomycin-5a-carboxylic acid and the nitrile and lower alkyl esters thereof.
14. A process according to any one of claims 1, 2 and 4, wherein starting materials are selected such as to manufacture 5a-methoxycarbonylbicyclomycin.
15. A process according to any one of claims 3 and 5, wherein starting materials are selected such as to manufacture Sa-methoxycarbonylbicyclomycin.
16. A process according to claim 1, wherein 5-nor-bicyclo-mycin-5-one is treated with methoxycarbonylmethylenetriphenyl-phosphorane to manufacture 5a-methoxycarbonylbicyclomycin.
17. 2-Oxa-7,9-diazabicyclo[4,2,2]decane compounds of the formula (I) wherein each of Ra, Rb, Rc and Rd individually represents hydrogen or oxa-(lower alkyl), oxa-(lower cycloalkyl), lower alkanoyl, lower cycloalkoxycarbonyl or aroyl with no more than 7 carbon atoms, or any two of the symbols Ra, Rb and Rc together represent carbonyl, lower alkylidene or mono-cyclic lower cycloalkylidene, X represents carboxyl, cyano, car-bamoyl, carbazoyl, lower alkoxycarbonyl, phenyl-(lower alkoxy) carbonyl, lower alkanoyl or benzoyl, whereby phenyl rings in the said radicals may be substituted by nitro, methoxy, lower alkyl and/or halogen, Y represents a hydrogen atom or has one of the meanings assigned to X, and n is 0 or 1, and of phar-maceutically acceptable salts of compounds which contain at least one carboxyl group, whenever prepared by the process claimed in any one of claims 1, 2 and 4, or by any process which is an obvious equivalent thereof.
18. 5a-Methoxycarbonylbicyclomycin, whenever prepared by the process claimed in claim 16 or by any process which is an obvious equivalent thereof.
CA283,708A 1976-08-02 1977-07-29 5.alpha.-BICYCLOMYCIN DERIVATIVES Expired CA1093071A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LU75516A LU75516A1 (en) 1976-08-02 1976-08-02
LU75516 1976-08-02

Publications (1)

Publication Number Publication Date
CA1093071A true CA1093071A (en) 1981-01-06

Family

ID=19728314

Family Applications (1)

Application Number Title Priority Date Filing Date
CA283,708A Expired CA1093071A (en) 1976-08-02 1977-07-29 5.alpha.-BICYCLOMYCIN DERIVATIVES

Country Status (15)

Country Link
US (1) US4145344A (en)
JP (1) JPS5318599A (en)
AT (1) AT352878B (en)
AU (1) AU514932B2 (en)
BE (1) BE857357A (en)
CA (1) CA1093071A (en)
DE (1) DE2734579A1 (en)
DK (1) DK344277A (en)
ES (1) ES461157A1 (en)
FR (1) FR2360595B1 (en)
GB (1) GB1542597A (en)
LU (1) LU75516A1 (en)
NL (1) NL7708547A (en)
SE (1) SE7708758A (en)
ZA (1) ZA7704627B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2722164A1 (en) * 1976-05-21 1977-12-22 Ciba Geigy Ag bicyclic compounds
AT124217T (en) * 1991-06-04 1995-07-15 Fujisawa Pharmaceutical Co Preventive / therapeutic composition for the pig pleuropneumonia.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4945093A (en) * 1972-09-08 1974-04-27

Also Published As

Publication number Publication date
SE7708758A (en) 1978-02-03
GB1542597A (en) 1979-03-21
ZA7704627B (en) 1978-06-28
DE2734579A1 (en) 1978-02-09
FR2360595A1 (en) 1978-03-03
US4145344A (en) 1979-03-20
FR2360595B1 (en) 1980-01-18
CA1093071A1 (en)
BE857357A1 (en)
ES461157A1 (en) 1978-12-01
DK344277A (en) 1978-02-03
JPS5318599A (en) 1978-02-20
AU2754277A (en) 1979-02-08
NL7708547A (en) 1978-02-06
LU75516A1 (en) 1978-02-13
ATA562877A (en) 1979-03-15
AU514932B2 (en) 1981-03-05
BE857357A (en) 1978-02-01
AT352878B (en) 1979-10-10

Similar Documents

Publication Publication Date Title
US3496163A (en) 7-halo-7-deoxylincomycins and process for preparing the same
Wagner et al. Preparation and synthetic utility of some organotin derivatives of nucleosides
Okabe et al. Synthesis of the dideoxynucleosides" ddC" and" CNT" from glutamic acid, ribonolactone, and pyrimidine bases
KR970000241B1 (en) Fluorocytidine derivatives, their preparation and medical p
Russell et al. Reactions of 2-acyloxyisobutyryl halides with nucleosides. II. Reactions of adenosine
JP3621097B2 (en) Sorbo pyranose sulfamate compounds exhibit anti-spasmodic
US5137876A (en) Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
EP0160391B1 (en) Carbapenem derivatives and compositions containing them
USRE34960E (en) Carbapenem compounds, and compositions containing them
US4515722A (en) Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents
EP0354583B1 (en) DC-88A derivatives
US5464826A (en) Method of treating tumors in mammals with 2',2'-difluoronucleosides
Verheyden et al. Halo sugar nucleosides. I. Iodination of the primary hydroxyl groups of nucleosides with methyltriphenoxyphosphonium iodide
US6579981B1 (en) Antiviral guanine derivatives
AU614082B2 (en) Nucleosides and nucleoside analogues, pharmaceutical composition and processes for the preparation of the compounds
CA2001715C (en) Carbocyclic nucleosides and nucleotides
US4234489A (en) Pyroglutamic acid derivatives and analogs
US4102904A (en) Intermediates for the preparation of antibacterial compounds
EP0269025A2 (en) Rebeccamycin analogs
FI93217C (en) Process for the preparation of a therapeutically active nucleoside derivatives of esters and amides
CA2077638A1 (en) N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n- alkynylheteroarylmacrolides having immunosuppressive activity
US5182374A (en) Clindamycin phosphate synthesis
US4474806A (en) Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents
HU182017B (en) Process for preparing 6-substituted thia-aza-derivatives
SU452961A3 (en) A process for preparing pirimidinnukleozidov

Legal Events

Date Code Title Description
MKEX Expiry